These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

949 related articles for article (PubMed ID: 26926507)

  • 1. [Impact of novel P2Y12 receptor inhibitors on platelet reactivity in acute coronary syndrome patients undergoing percutaneous coronary intervention].
    Chong Tou TJ; Liu PM; Wang JF; Sio Cham ZC; O U YF; Lei Sio ZW; Lei Put PZ; Lei Sok SM; Zhou SX; Wu W
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Feb; 44(2):138-43. PubMed ID: 26926507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
    Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
    J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
    Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
    J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High and low on-treatment platelet reactivity to P2Y
    Ferreiro JL; Vivas D; De La Hera JM; Marcano AL; Lugo LM; Gómez-Polo JC; Silva I; Tello-Montoliu A; Marín F; Roldán I
    Thromb Res; 2019 Mar; 175():95-101. PubMed ID: 30738371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study.
    Hauguel-Moreau M; Boccara F; Boyd A; Salem JE; Brugier D; Curjol A; Hulot JS; Kerneis M; Galier S; Cohen A; Montalescot G; Collet JP; Silvain J
    Eur Heart J; 2017 Jun; 38(21):1676-1686. PubMed ID: 28065907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
    Aradi D; Tornyos A; Pintér T; Vorobcsuk A; Kónyi A; Faluközy J; Veress G; Magyari B; Horváth IG; Komócsi A
    J Am Coll Cardiol; 2014 Mar; 63(11):1061-70. PubMed ID: 24486281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
    O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
    Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensified P2Y12 inhibition for high-on treatment platelet reactivity.
    Mshelbwala FS; Hugenberg DW; Kreutz RP
    J Thromb Thrombolysis; 2020 Oct; 50(3):619-627. PubMed ID: 32152791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized Comparison of Oral P2Y
    Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
    JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
    Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes.
    Joshi RR; Hossain R; Morton AC; Ecob R; Judge HM; Wales C; Walker JV; Karunakaran A; Storey RF
    Platelets; 2014; 25(6):416-22. PubMed ID: 24111601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial.
    Diodati JG; Saucedo JF; Cardillo TE; Jakubowski JA; Henneges C; Effron MB; Lipkin FR; Walker JR; Duvvuru S; Sundseth SS; Fisher HN; Angiolillo DJ
    Thromb Haemost; 2014 Aug; 112(2):311-22. PubMed ID: 24718367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome.
    Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C
    Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study.
    Jin C; Kim MH; Bang J; Serebruany V
    Cardiology; 2017; 138(4):201-206. PubMed ID: 28810251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
    Saucedo JF; Angiolillo DJ; DeRaad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Duvvuru S; Effron MB;
    Thromb Haemost; 2013 Feb; 109(2):347-55. PubMed ID: 23223867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
    Franchi F; Faz GT; Rollini F; Park Y; Cho JR; Thano E; Hu J; Kureti M; Aggarwal N; Durairaj A; Been L; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2016 Jun; 9(11):1089-98. PubMed ID: 27013060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VERifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel.
    Cubero Gómez JM; Acosta Martínez J; Mendias Benítez C; Díaz De La Llera LS; Fernández-Quero M; Guisado Rasco A; Villa Gil-Ortega M; Sánchez González Á
    Acta Cardiol; 2015 Dec; 70(6):728-34. PubMed ID: 26717223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic effect of prasugrel 5 mg vs clopidogrel 150 mg in elderly patients with high on-clopidogrel platelet reactivity.
    Alexopoulos D; Xanthopoulou I; Plakomyti TE; Theodoropoulos KC; Mavronasiou E; Damelou A; Hahalis G; Davlouros P
    Am Heart J; 2013 Jan; 165(1):73-9. PubMed ID: 23237136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor in comparison to clopidogrel: a retrospective pharmacodynamic analysis.
    Selhorst G; Schmidtler F; Ott A; Hitzke E; Tomelden J; Antoni D; Hoffmann E; Rieber J
    Platelets; 2019; 30(3):341-347. PubMed ID: 29521570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching acute coronary syndrome patients from prasugrel to clopidogrel.
    Kerneis M; Silvain J; Abtan J; Cayla G; O'Connor SA; Barthélémy O; Vignalou JB; Beygui F; Brugier D; Martin R; Collet JP; Montalescot G
    JACC Cardiovasc Interv; 2013 Feb; 6(2):158-65. PubMed ID: 23428007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.